This study involves research. You are being asked to participate in this research study to have your temperature taken. The purpose of the study is to collect data to test a temperature measurement module that is part of medical study device that measure's human body temperature.

The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with investigational urine testing. Specifically, we are examining whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.

This Phase 3 study, comprising a double-blind, placebo-controlled treatment period of up to 48 weeks, will assess the efficacy and safety of seralutinib versus placebo when added to background PAH disease-specific medication in adult PAH subjects who are WHO FC II or III. The primary objective of the study is to assess the efficacy of seralutinib relative to placebo with a primary endpoint of change from baseline to Week 24 in 6MWD.

This trial is for people with melanoma. This trial is testing the V940 (mRNA-4157) vaccine given in combination with pembrolizumab in people who have surgery to remove their melanoma. The vaccine has multiple patient-specific neoantigens that could improve the recurrence-free survival after the surgery. Each participant will participate in the study for approximately 7 years from the time the participant provides full documented informed consent through the final contact. There is a screening window of up tp 56 days where the participants receives tumor scan, brain scan, pathology report, hematology, coagulation tests, hormones, enzymes, and blood for genetic sequencing and vaccine generation. After a screening period of up to 56 days, each participant will be receiving assigned intervention for a maximum of approximately 56 weeks. The participants will be assigned to the two arms in the study randomly after the genetic testing confirms eligibility based on disease risk and age. Arm A will receive and a V940 injection in the muscle every 3 weeks for a total of 9 doses and pembrolizumab ever 6 weeks for a total of 9 cycles. Arm B will receive Placebo every 3 weeks for 9 dose and pembrolizumab every 6 weeks for 9 cycles. After the end of treatment each participant will be followed for approximately 6 years. V940 monotherapy has been well tolerated, but injection site observations included edema and pain/tenderness, and systemic inflammatory observations, including flu like symptoms, fever, fatigue, and myalgias/arthralgias, all of which have typically resolved 1 to 2 days after dosing). The clinical safety profile of V940 does not significantly overlap with pembrolizumab. Pembrolizumab has a positive benefit-risk profile and is well tolerated. Some possible risks associated with pembrolizumab are fatigue, pruritus , rash , diarrhea, nausea, hypothyroidism, pneumonitis, colitis, pyrexia and autoimmune hepatitis, pneumonia, adrenal insufficiency and hyponatremia.

This study is for patients that have been diagnosed with early-stage (Stage I or II) Hodgkin lymphoma (HL)(cHL). The main purpose of this study is to compare the effects, good and/or bad, of brentuximab vedotin and nivolumab (Bv-NIVO) against standard therapy for people with HL to find out which is better. Participants can expect to be in the study for up to 54 months.

In this study, the participants will take pembrolizumab for 24 months or get pembrolizumab plus a course of radiation therapy for 24 months until the cancer progresses. After the study treatment is finished, the study doctor will continue to follow the participants condition for a total of 3 years. Some risks in this study is that pembrolizumab with radiation may not be as good as the usual approach for cancer shirking or stabilizing. Some risks associated with pembrolizumab and radiation which are reduction in blood counts, mouth or throat pain and difficulty swallowing. The potential benefit of this study is that radiation and chemotherapy/pembrolizumab can be effective at shrinking or stabilizing the cancer. The purpose of this study is to compare using pembrolizumab with radiation to pembrolizumab without radiation.

The purpose of this study is to evaluate the efficacy and safety of upadicitinib in adults and adolescents with severe alopecia areata. Participation in this research study will take approximately 168 weeks with 17 visits in that time. This research study includes three phases; a screening phase, treatment phase, and a follow-up phase. The length of the screening period varies from 1 to 35 days, depending on therapies that must be washed out or discontinued before initiation of treatment. Patients who meet all eligibility criteria will be randomized to receive upadicitinib or placebo for the first 24 weeks. At week 24, all patients will receive upadicitinib until week 160. The post-treatment follow-up visit will occur approximately 30 days after the last study drug dose.

The study is for a patient that have been diagnosed with multiple myeloma. The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).Overall rationale of the study is that combination treatments of talquetamab, daratumumab, pomalidomide and dexamethasone may lead to enhanced clinical responses in treatment of relapsed or refractory multiple myeloma through multiple mechanisms of action. The study is divided into 3 phases: screening, treatment (until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first), and posttreatment follow-up (until death, withdrawal of consent, loss to follow-up, or end of the study, whichever occurs first).

This project examines how to improve speech understanding with cochlear implants (CIs), particularly for older CI recipients. While older individuals benefit from CI technology, performance is poorer than that of younger implanted adults for difficult listening tasks. The mechanisms that contribute to this variability are not well-understood. The current project examines how differences in brain structure and function may contribute to success with a cochlear implant. To compare, we will also be examining how older patients without cochlear implants understand speech in difficult listening situations.

Smoking is one of the main public health problems. Smoking cessation is difficult because of nicotine dependence. Repetitive transcranial magnetic stimulation (rTMS) over the frontal head has shown to be effective in the reduction of cigarette consumption and craving. In this study, we will evaluate the efficiency of a new form of rTMS called intermittent theta-burst stimulation (iTBS) for smoking cessation.